TY - JOUR
T1 - IRAK2 Has a Critical Role in Promoting Feed-Forward Amplification of Epidermal Inflammatory Responses
AU - Shao, Shuai
AU - Tsoi, Lam C.
AU - Swindell, William R.
AU - Chen, Jiaoling
AU - Uppala, Ranjitha
AU - Billi, Allison C.
AU - Xing, Xianying
AU - Zeng, Chang
AU - Sarkar, Mrinal K.
AU - Wasikowski, Rachael
AU - Jiang, Yanyun
AU - Kirma, Joseph
AU - Sun, Jingru
AU - Plazyo, Olesya
AU - Wang, Gang
AU - Harms, Paul W.
AU - Voorhees, John J.
AU - Ward, Nicole L.
AU - Ma, Feiyang
AU - Pellegrini, Matteo
AU - Merleev, Alexander
AU - Perez White, Bethany E.
AU - Modlin, Robert L.
AU - Andersen, Bogi
AU - Maverakis, Emanual
AU - Weidinger, Stephan
AU - Kahlenberg, J. Michelle
AU - Gudjonsson, Johann E.
N1 - Funding Information:
This work was supported by NIH P30 AR075043 (JEG), NIH RO1 AR069071 (JEG), an National Psoriasis Foundation Psoriasis Prevention Initiative award (JEG, JMK, NLW, EM, LCT), the Taubman Institute Innovation Project program (JEG and JMK), the Babcock Endowment Fund (LCT, MKS, JEG), the National Institute of Arthritis and Musculoskeletal and Skin Diseases AR060802 (JEG) and AR072129 (LCT), National Psoriasis Foundation Translational Grant (MKS), National Institute of Allergy and Infectious Diseases under Award Number R01-AR06 (JEG), and the Parfet Emerging Scholar Award (JMK). LCT is supported by the Dermatology Foundation, Arthritis National Research Foundation , and National Psoriasis Foundation.
Funding Information:
This work received support through BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis), a project funded by the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 821511. SW is coprincipal investigator of the German Atopic Eczema Registry TREATgermany; has received institutional research grants from Sanofi Deutschland GmbH, LEO Pharma, and La Roche Posay; has performed consultancies for Sanofi-Genzyme, Regeneron Pharmaceuticals, LEO Pharma, AbbVie, Pfizer, Eli Lilly, Kymab, and Novartis; has lectured at educational events sponsored by Sanofi-Genzyme, Regeneron Pharmaceuticals, LEO Pharma, AbbVie, Novartis, and Galderma; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic eczema. JMK has served on ad boards for AstraZeneca, Provention Bio, Aurinia Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Viela Bio, and Ventus Therapeutics and has grants from Bristol Myers Squibb and Q32 Bio. JEG has received honoraria from AnaptysBio, Bristol-Myers Squibb Celgene, Sanofi, AstraZeneca, Eli Lilly, Novartis, and Almirall and research grants from Eli Lilly, Kyowa Kirin, Almirall, and Bristol-Myers Squibb Celgene. The other authors state no conflict of interest.
Publisher Copyright:
© 2021 The Authors
PY - 2021
Y1 - 2021
N2 - Many inflammatory skin diseases are characterized by altered epidermal differentiation. Whether this altered differentiation promotes inflammatory responses has been unknown. Here, we show that IRAK2, a member of the signaling complex downstream of IL-1 and IL-36, correlates positively with disease severity in both atopic dermatitis and psoriasis. Inhibition of epidermal IRAK2 normalizes differentiation and inflammation in two mouse models of psoriasis- and atopic dermatitis-like inflammation. Specifically, we demonstrate that IRAK2 ties together proinflammatory and differentiation-dependent responses and show that this function of IRAK2 is specific to keratinocytes and acts through the differentiation-associated transcription factor ZNF750. Taken together, our findings suggest that IRAK2 has a critical role in promoting feed-forward amplification of inflammatory responses in skin through modulation of differentiation pathways and inflammatory responses.
AB - Many inflammatory skin diseases are characterized by altered epidermal differentiation. Whether this altered differentiation promotes inflammatory responses has been unknown. Here, we show that IRAK2, a member of the signaling complex downstream of IL-1 and IL-36, correlates positively with disease severity in both atopic dermatitis and psoriasis. Inhibition of epidermal IRAK2 normalizes differentiation and inflammation in two mouse models of psoriasis- and atopic dermatitis-like inflammation. Specifically, we demonstrate that IRAK2 ties together proinflammatory and differentiation-dependent responses and show that this function of IRAK2 is specific to keratinocytes and acts through the differentiation-associated transcription factor ZNF750. Taken together, our findings suggest that IRAK2 has a critical role in promoting feed-forward amplification of inflammatory responses in skin through modulation of differentiation pathways and inflammatory responses.
UR - http://www.scopus.com/inward/record.url?scp=85105447387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105447387&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2021.03.019
DO - 10.1016/j.jid.2021.03.019
M3 - Article
C2 - 33864770
AN - SCOPUS:85105447387
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
SN - 0022-202X
ER -